Company / R&D per Share
Larimar Therapeutics, Inc. R&D per Share History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.10
FY2019
5-year range
$0.42 / $2.00
FY2015-FY2019
Trend
-24.6%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2.00 to $1.10 over the past 2 years.
Based on SEC 10-K filings.
1.10 in FY2019 with a 5-year CAGR of -41.4%.
Declined from $2.00 to $1.10 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- -41.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, r&d per share decreased 24.6% year-over-year.
- Peak r&d per share was recorded in FY2014.
- Lowest r&d per share in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $1.10 | -24.6% |
| FY2018 | $1.45 | -27.3% |
| FY2017 | $2.00 | +98.7% |
| FY2016 | $1.01 | +140.6% |
| FY2015 | $0.42 | -97.4% |
| FY2014 | $15.83 | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026